Nov 16, 2023 / 10:00AM GMT
Operator
Presentation is from Fennec Pharmaceuticals, and we have Adrian Haigh, this year.
Adrian Haigh - Fennec Pharmaceuticals Inc. - COO
Thanks. Morning, everybody. Just the Safe Harbor statement, just a bit of background on me. First of all, I've been a Board Director Fennec for almost 10 years. I gave up the day job where I was head of PTC international, back in January, I spent six months retired but joined full time as Chief Operating Officer in August of this year.
So PEDMARK is a commercial stage pharmaceutical company. We've got one asset, which is PEDMARK, which is a specially formulated solution of sodium thiosulfate indicated to prevent cyst platinum induced hearing loss in pediatric patients. We have Orange Book Patent exclusivity in the US until 2039 on the formulations. We have seven years off-drug exclusivity in the US, and we have a PUMA, a pediatric use marketing authorization in Europe.
We launched commercially in the US in October of last year and we expect to launch in Europe in June of next year. The reason for that is we had
Fennec Pharmaceuticals Inc at Jefferies London Healthcare Conference Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers